Quantitative measurement of the histological features of alpha-1 antitrypsin deficiency-associated liver disease in biopsy specimens

PLoS One. 2021 Aug 16;16(8):e0256117. doi: 10.1371/journal.pone.0256117. eCollection 2021.

Abstract

Background: Pathological mutations in Alpha-1 Antitrypsin (AAT) protein cause retention of toxic polymers in the hepatocyte endoplasmic reticulum. The risk for cirrhosis in AAT deficiency is likely directly related to retention of these polymers within the liver. Polymers are classically identified on liver biopsy as inclusion bodies by periodic acid schiff staining after diastase treatment and immunohistochemistry. However, characterization of the polymer burden within a biopsy sample is limited to a semi-quantitative scale as described by a pathologist. Better methods to quantify polymer are needed to advance our understanding of pathogenesis of disease. Therefore, we developed a method to quantify polymer aggregation from standard histologic specimens. In addition, we sought to understand the relationship of polymer burden and other histologic findings to the presence of liver fibrosis.

Methods: Liver samples from a well-categorized AATD cohort were used to develop histo-morphometric tools to measure protein aggregation.

Results: Whole-slide morphometry reliably quantifies aggregates in AATD individuals. Despite very low levels of inclusions present (0-0.41%), accumulation of globules is not linear and is associated with higher fibrosis stages. Immunohistochemistry demonstrates that fibrosis is associated with polymer accumulation and not total AAT. A proportion of patients were found to be "heavy accumulators" with a polymer burden above the upper 25% of normal distribution. Males had significantly more liver inclusions and polymer than females. These measurements also highlight interrelated phenotypes of hepatocellular degeneration and autophagy in AATD liver disease.

Conclusion: Quantitative inclusion analysis measures AAT accumulation in liver biopsy specimens. Quantification of polymer may identify individuals at risk for progressive disease and candidates for therapeutic interventions. Furthermore, these methods may be useful for evaluating efficacy of drugs targeting accumulation of AAT.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / metabolism
  • Biopsy
  • Female
  • Humans
  • Immunohistochemistry
  • Inclusion Bodies / metabolism
  • Inclusion Bodies / pathology*
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / metabolism
  • Liver Cirrhosis / pathology*
  • Liver Diseases / etiology
  • Liver Diseases / metabolism
  • Liver Diseases / pathology*
  • Male
  • Middle Aged
  • Mutation*
  • Prognosis
  • alpha 1-Antitrypsin Deficiency / complications
  • alpha 1-Antitrypsin Deficiency / metabolism
  • alpha 1-Antitrypsin Deficiency / pathology*

Substances

  • Biomarkers

Grants and funding

Alpha 1 Foundation Professoship (MB), NIH NCATS University of Florida CTSA award L1TR001427 (VC, MB). The funders had no role in study design, data collection and analysis, decision to publish, or reparation of the manuscript. Dr. Collinsworth is currently affiliated with Advanced Pathology Solutions however she was faculty at University of Florida during the work included in this project. Advanced Pathology Solutions was not involved in the funding, design or execution of the work presented and did not provide relevant salary or other support to Dr. Collinsworth or any members of the research team during her work on this project.